EXTON, Pa., April 11, 2019 /PRNewswire/ -- Almirall was recognized this week with the Distinguished Corporate Leadership award by the American Skin Association (ASA).
Ron Menezes, President and General Manager of Almirall LLC, accepted the award on behalf of the more than 1,800 employees of the company from around the globe. He spoke about Almirall's new corporate purpose which aligns with the mission of the ASA. To illustrate this, he gave a moving presentation about a real acne patient.
"This was a 16-year-old male patient with severe acne who was hiding away from the world," explained Ron Menezes. "He wouldn't meet the eyes of his dermatologist when he first visited them to get help. At his first follow-up visit four weeks later he already had a significant improvement, but more importantly he had 'come out of his shell' as his mother said. He was reaching out to friends again and was socializing, and she was relieved and happy to see that."
The mission of the ASA is to advance research, champion skin health and drive public awareness about skin disease. Over the course of their 32-year history to date, the visionary leadership of the Association has supported the work of over 300 scientists and investigators by committing more than $50 million to advance dermatological research. Their successful projects have included the establishment of a model research facility at Weill Cornell medical college and providing free instruction on sun protection and skin health through award-winning public school programs.
Dr. David Norris, University of Colorado professor and President of the board of directors for the ASA, presented Ron Menezes with the Corporate Leadership award, highlighting Almirall's contribution to the field of dermatology. "I'm impressed with Almirall's spectrum of new treatments for important skin diseases, in some areas that we as clinicians haven't had new treatments in for years. Through pharmacological innovation and strong commitment to global healthcare partnerships, Almirall is dedicated to providing the tools, knowledge and science to improve the health of patients worldwide."
The award to Almirall by the ASA is the latest achievement in the company's goal of being recognized as a leader in medical dermatology in the US and globally.
Peter Guenter, CEO of Almirall SA, said, "We are pleased to have received this award from such an esteemed organization. The ASA mission aligns with the new Almirall corporate purpose: 'Transform the patients' world by helping them realize their hopes and dreams for a healthy life.' We look forward to working with them, and the rest of the dermatology community, to make this purpose a reality."
For more information on Almirall, please visit Almirall US.
Almirall is a leading skin health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals in their quest to find continuous improvement to treatments, by bringing our innovative solutions where they are needed. The company, founded in 1943 and with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has become a key element of value creation to society according to its commitment with its major shareholders and its decision to help others, to understand their challenges and to use science to help provide them with solutions for real life health challenges.
Corporate Communications Contact:
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.